Prothena Co. plc (NASDAQ: PRTA) Receives “Buy” Consensus Rating from Brokerages

0

Shares of Prothena Co. plc (NASDAQ: PRTA) have achieved a consensus “Buy” rating from the ten brokerages that cover the company, reports MarketBeat.com. Two research analysts rated the stock with a conservation rating and eight gave the company a buy rating. The one-year average price target among brokerage firms that reported on the stock in the past year is $ 56.70.

A number of equity research analysts commented on the company. Bank of America downgraded Prothena from an “underperforming” to a “neutral” rating and raised its price target for the company from $ 12.00 to $ 49.00 in a research report released on Friday June 18. Cantor Fitzgerald raised his price target on Prothena shares from $ 63.00 to $ 70.00 and assigned the company an “overweight” rating in a research note on Thursday, July 15. Royal Bank of Canada increased its price target on Prothena from $ 50.00 to $ 59.00 and rated the stock as “outperforming” in a report released on Monday July 19th. HC Wainwright raised its target price on Prothena shares from $ 58.00 to $ 75 and gave the share a “buy” rating in a research note on Tuesday, July 13. Finally, Oppenheimer raised its price target on Prothena shares from $ 54.00 to $ 76.00 and rated the stock as “outperforming” in a report released on Tuesday, July 13.

In addition, director Christopher S. Henney sold 11,108 shares in a transaction that took place on Wednesday, July 14. The stock was sold for an average price of $ 55.46, for a total value of $ 616,049.68. As a result of the sale, the director now directly owns 11,108 shares of the company, valued at $ 616,049.68. The sale was disclosed in a document filed with the SEC, which is available at this link. In addition, director Christopher S. Henney sold 23,892 shares of the company in a transaction dated Monday, July 12. The shares were sold at an average price of $ 55.51, for a total transaction of $ 1,326,244.92. Following the closing of the sale, the director now directly owns 17,500 shares of the company, valued at $ 971,425. Disclosure of this sale can be found here. In the past three months, insiders have sold 162,250 shares of the company valued at $ 7,833,842. 30.40% of the shares are held by insiders.

A number of large investors have recently changed their holdings to PRTA. EAM Investors LLC purchased a new position in Prothena shares in the first quarter valued at approximately $ 1,549,000. Rafferty Asset Management LLC acquired a new position in Prothena in the first quarter valued at approximately $ 1,032,000. Palo Alto Investors LP increased its stake in Prothena by 3.0% during the first quarter. Palo Alto Investors LP now owns 1,742,505 shares of the biotech company valued at $ 43,772,000 after purchasing an additional 50,700 shares in the last quarter. ClariVest Asset Management LLC strengthened its position in Prothena shares by 68,333.3% in the 1st quarter. ClariVest Asset Management LLC now owns 28,742 shares of the biotech company valued at $ 722,000 after purchasing an additional 28,700 shares during the period. Finally, Citigroup Inc. increased its position in Prothena by 160.5% in the 4th quarter. Citigroup Inc. now owns 7,572 shares of the biotech company valued at $ 91,000 after purchasing an additional 4,665 shares in the last quarter. Institutional investors hold 90.49% of the shares of the company.

NASDAQ PRTA open for $ 51.48 Tuesday. The company has a 50-day moving average of $ 43.63. The company has a market cap of $ 2.27 billion, a P / E ratio of -16.55, a PEG ratio of 100.16 and a beta of 1.58. Prothena has a 12 month low of $ 9.67 and a 12 month high of $ 67.08.

Prothena (NASDAQ: PRTA) last released its quarterly earnings data on Monday, May 10. The biotech company reported ($ 0.91) earnings per share (EPS) for the quarter, missing Zacks’ consensus estimate of $ 0.80 ($ 0.11). The company posted revenue of $ 0.16 million in the quarter, compared to the consensus estimate of $ 0.17 million. Prothena had a negative net margin of 14,255.73% and a negative return on equity of 57.65%. On average, analysts expect Prothena to post EPS of 0.22 for the current year.

About Prothena

Prothena Corporation plc, an advanced-stage clinical company, is focused on the discovery and development of new therapies for life-threatening diseases in the United States. The company is involved in the development of PRX002 / RG7935 which is in a phase 2 clinical trial for the treatment of Parkinson’s disease and other associated synucleinopathies; and PRX004, an antibody that is in a Phase 1 clinical trial for the treatment of ATTR amyloidosis.

Recommended Story: Growth and Income Fund

Analyst recommendations for Prothena (NASDAQ: PRTA)

This instant news alert was powered by storytelling technology and MarketBeat financial data to provide readers with the fastest, most accurate reports. This story was reviewed by the MarketBeat editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Featured article: What is the operating result?

7 electric vehicle (EV) stocks ready to bounce back

The electric vehicle (EV) industry was almost as sparkling as “pandemic stocks” in 2020. It wasn’t that the EV industry was dormant during the Trump administration.

But, as the saying goes, elections have consequences. And Wall Street understands they can make money in any jurisdiction. And as a bet that Joe Biden would win the presidency, stocks of electric vehicles have skyrocketed.

For starters, the Biden administration has already said it will prioritize climate change like no administration has ever done. And one way to do that is to encourage the production and purchase of electric vehicles.

And to take advantage of this shift towards electric vehicle inventory, many private companies have rushed to get into the action. The preferred way for many of these companies to go public was through a Special Purpose Acquisition Company (SPAC). A SPAC is essentially a shortcut to the traditional IPO process.

However, what increases frequently decreases and since the end of February, stocks of electric vehicles have been abused. But this creates an opportunity as the electric vehicle is expected to experience further exceptional growth over the next five years.

To help you take advantage of it, we’ve created this special showcase that includes seven actions that look like they’re ready to be taken to the next level.

Check out the “7 Electric Vehicle (EV) Actions Ready to Bounce Back”.


Source link

Leave A Reply

Your email address will not be published.